Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Language
Publication year range
2.
Development ; 147(12)2020 06 17.
Article in English | MEDLINE | ID: mdl-32439760

ABSTRACT

Physical forces are important participants in the cellular dynamics that shape developing organs. During heart formation, for example, contractility and blood flow generate biomechanical cues that influence patterns of cell behavior. Here, we address the interplay between function and form during the assembly of the cardiac outflow tract (OFT), a crucial connection between the heart and vasculature that develops while circulation is under way. In zebrafish, we find that the OFT expands via accrual of both endocardial and myocardial cells. However, when cardiac function is disrupted, OFT endocardial growth ceases, accompanied by reduced proliferation and reduced addition of cells from adjacent vessels. The flow-responsive TGFß receptor Acvrl1 is required for addition of endocardial cells, but not for their proliferation, indicating distinct modes of function-dependent regulation for each of these essential cell behaviors. Together, our results indicate that cardiac function modulates OFT morphogenesis by triggering endocardial cell accumulation that induces OFT lumen expansion and shapes OFT dimensions. Moreover, these morphogenetic mechanisms provide new perspectives regarding the potential causes of cardiac birth defects.


Subject(s)
Endocardium/metabolism , Heart/physiology , Zebrafish/metabolism , Activin Receptors/antagonists & inhibitors , Activin Receptors/genetics , Activin Receptors/metabolism , Animals , Animals, Genetically Modified/growth & development , Animals, Genetically Modified/metabolism , Cell Proliferation , Embryo, Nonmammalian/cytology , Embryo, Nonmammalian/metabolism , Endocardium/cytology , Heart/anatomy & histology , Heart/growth & development , Morpholinos/metabolism , Troponin T/antagonists & inhibitors , Troponin T/genetics , Troponin T/metabolism , Zebrafish/growth & development , Zebrafish Proteins/antagonists & inhibitors , Zebrafish Proteins/genetics , Zebrafish Proteins/metabolism
3.
Angiogenesis ; 23(2): 203-220, 2020 05.
Article in English | MEDLINE | ID: mdl-31828546

ABSTRACT

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal-dominant vascular disorder characterized by development of high-flow arteriovenous malformations (AVMs) that can lead to stroke or high-output heart failure. HHT2 is caused by heterozygous mutations in ACVRL1, which encodes an endothelial cell bone morphogenetic protein (BMP) receptor, ALK1. BMP9 and BMP10 are established ALK1 ligands. However, the unique and overlapping roles of these ligands remain poorly understood. To define the physiologically relevant ALK1 ligand(s) required for vascular development and maintenance, we generated zebrafish harboring mutations in bmp9 and duplicate BMP10 paralogs, bmp10 and bmp10-like. bmp9 mutants survive to adulthood with no overt phenotype. In contrast, combined loss of bmp10 and bmp10-like results in embryonic lethal cranial AVMs indistinguishable from acvrl1 mutants. However, despite embryonic functional redundancy of bmp10 and bmp10-like, bmp10 encodes the only required Alk1 ligand in the juvenile-to-adult period. bmp10 mutants exhibit blood vessel abnormalities in anterior skin and liver, heart dysmorphology, and premature death, and vascular defects correlate with increased cardiac output. Together, our findings support a unique role for Bmp10 as a non-redundant Alk1 ligand required to maintain the post-embryonic vasculature and establish zebrafish bmp10 mutants as a model for AVM-associated high-output heart failure, which is an increasingly recognized complication of severe liver involvement in HHT2.


Subject(s)
Activin Receptors/metabolism , Blood Vessels/growth & development , Blood Vessels/physiology , Bone Morphogenetic Proteins/physiology , Neovascularization, Physiologic/genetics , Regeneration/genetics , Zebrafish Proteins/metabolism , Activin Receptors/genetics , Animals , Animals, Genetically Modified , Arteriovenous Malformations/genetics , Arteriovenous Malformations/metabolism , Arteriovenous Malformations/pathology , Bone Morphogenetic Proteins/genetics , Cell Differentiation/genetics , Embryo, Nonmammalian , Endothelial Cells/physiology , Gene Expression Regulation, Developmental , Signal Transduction/genetics , Zebrafish , Zebrafish Proteins/genetics , Zebrafish Proteins/physiology
4.
Angiogenesis ; 20(4): 663-672, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28638990

ABSTRACT

De novo synthesis of cytoskeleton-regulatory proteins triggered by the megakaryoblastic leukemia (MKL)/serum response factor (SRF) transcriptional system in response to pro-angiogenic growth factors lies at the heart of endothelial cell (EC) migration (a critical element of angiogenesis) and neovascularization. This study explores whether pharmacological intervention of MKL/SRF signaling axis by CCG-1423 is able to suppress angiogenesis. Our studies show that CCG-1423 inhibits migration and cord morphogenesis of EC in vitro and sprouting angiogenesis ex vivo and in vivo, suggesting CCG-1423 could be a novel anti-angiogenic agent. Kymography analyses of membrane dynamics of EC revealed that CCG-1423 treatment causes a major defect in membrane protrusion. CCG-1423 treatment led to attenuated expression of several actin-binding proteins that are important for driving membrane protrusion including ArpC2, VASP, and profilin1 (Pfn1) with the most drastic effect seen on the expression of Pfn1. Finally, depletion of Pfn1 alone is also sufficient for a dramatic decrease in sprouting angiogenesis of EC in vitro and ex vivo, further suggesting that Pfn1 depletion may be one of the mechanisms of the anti-angiogenic action of CCG-1423.


Subject(s)
Anilides/pharmacology , Benzamides/pharmacology , Cell Movement/drug effects , Endothelial Cells/cytology , Endothelial Cells/metabolism , Neovascularization, Physiologic/drug effects , Serum Response Factor/metabolism , Signal Transduction/drug effects , Trans-Activators/metabolism , Actins/metabolism , Angiogenesis Inhibitors/pharmacology , Angiogenesis Inhibitors/therapeutic use , Animals , Cell Line , Cell Surface Extensions/drug effects , Cell Surface Extensions/metabolism , Embryo, Nonmammalian/drug effects , Embryo, Nonmammalian/metabolism , Endothelial Cells/drug effects , Humans , Mice, Knockout , Profilins/metabolism , Zebrafish/embryology
SELECTION OF CITATIONS
SEARCH DETAIL